In this video, Sara M. Tolaney, MD, MPH, breast medical oncologist at Dana Farber Cancer Institute, shared her perspectives on data from the TBCRC 048 trial presented during the ASCO20 Virtual Scientific Program. In TBCRC 048, the single-agent olaparib (Lynparza; AstraZeneca, Merck) met its primary endpoint in both study cohorts and showed a clinically meaningful response in patients with metastatic breast cancer with somatic BRCA1/2 or germline PALB2 mutations. However, there was not a meaningful response for patients with ATM or CHEK2 mutations. “The studies demonstrated a little over 50% objective response rate in those patients with somatic BRCA mutations, which occurs in up to 10% of our patients with metastatic breast cancer. Given these findings, I would consider using olaparib in those patients with somatic BRCA alterationsTung NM, et al. Abstract 1002. Presented at: ASCO20 Virtual Scientific Program; May 29 to 31, 2020.Tolaney reports consultant/advisory roles with AbbVie, Anthenex, AstraZeneca, Bristol-Myers Squibb, Celldex, Eisai, G1 Therapeutics, Genentech/Roche, Immunomedics, Lilly, Merck, Nanostring, Nektar, Novartis, Odonate, Paxman, Pfizer, Puma, Sanofi and Silverback Therapeutics; and receiving institutional research funds from Cyclacel and Exelixis; and honorarium from Seattle Genetics.